
Although more drug makers are settling patent infringement lawsuits, the U.S. Federal Trade Commission found that the number of so-called pay-to-delay settlements — which the agency argues unfairly robs Americans of lower-cost alternatives to their prescription medicines — remain very low.
In discussing the findings, which were from fiscal year 2017, agency officials maintained the decline underscores the effects of a 2012 U.S. Supreme Court ruling that such deals can be subject to review for anti-competitive agreements. Since then, the FTC has become more aggressive in challenging some patent settlements between brand-name and generic drug makers.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.